

RECEIVED
CENTRAL FAX CENTER

SEP 27 2005

Pfizer Inc.
150 East 42nd Street
New York, NY 10017

Facsimile Transmission

NOTICE OF CONFIDENTIALITY

This transmission is intended only for the use of the Addressee and may contain information that is: 1. Subject to attorney/client privilege: 2. Attorney work product: or 3. Confidential. If you are not the intended recipient, you are hereby notified that any dissemination, distribution or copying of the information contained in this facsimile is strictly unauthorized and prohibited. If you have received this facsimile in error, please notify us immediately by collect telephone call to the sender named below. Thank you.

To: U.S.P.T.O.

Location: Alexandria, Virginia

Facsimile Telephone: 273-8300

571-

No. of Pages: (including this page)

16

From: Mary J. Hosley

Department Name: Legal Division

Charge No.: 88424

Facsimile Telephone: (212) 573-1939

Date: September 27, 2005

Time (New York)

TO CONFIRM RECEIPT OF TRANSMISSION, CALL 212 733-0460

Supplemental Preliminary Amendment

SEP 27 2005

PTO/SB/21 (09-04)

Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office, U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no person is required to respond to a collection of information unless it displays a valid OMB control number.

TRANSMITTAL FORM (to be used for all correspondence after initial filing)	Application Number	10/800,328
	Filing Date	March 12, 2004
	First Named Inventor	Bright, et al
	Art Unit	Unknown
	Examiner Name	Unknown
	Attorney Docket Number	PC25322A
Total Number of Pages in This Submission	15	

ENCLOSURES (Check all that apply)		
<input type="checkbox"/> Fee Transmittal Form <input type="checkbox"/> Fee Attached <input type="checkbox"/> Amendment/Reply <input type="checkbox"/> After Final <input type="checkbox"/> Affidavits/declaration(s) <input type="checkbox"/> Extension of Time Request <input type="checkbox"/> Express Abandonment Request <input type="checkbox"/> Information Disclosure Statement <input type="checkbox"/> Certified Copy of Priority Document(s) <input type="checkbox"/> Reply to Missing Parts/Incomplete Application <input type="checkbox"/> Reply to Missing Parts under 37 CFR 1.52 or 1.53	<input type="checkbox"/> Drawing(s) <input type="checkbox"/> Licensing-related Papers <input type="checkbox"/> Petition <input type="checkbox"/> Petition to Convert to a Provisional Application <input type="checkbox"/> Power of Attorney, Revocation <input type="checkbox"/> Change of Correspondence Address <input type="checkbox"/> Terminal Disclaimer <input type="checkbox"/> Request for Refund <input type="checkbox"/> CD, Number of CD(s) _____ <input type="checkbox"/> Landscape Table on CD	<input type="checkbox"/> After Allowance Communication to TC <input type="checkbox"/> Appeal Communication to Board of Appeals and Interferences <input type="checkbox"/> Appeal Communication to TC (Appeal Notice, Brief, Reply Brief) <input type="checkbox"/> Proprietary Information <input type="checkbox"/> Status Letter <input checked="" type="checkbox"/> Other Enclosure(s) (please identify below):
Remarks Supplemental Preliminary Amendment		

SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT			
Firm Name	Pfizer, Inc		
Signature	<i>Mary J. Hosley</i>		
Printed name	Mary J. Hosley		
Date	26 September 2005	Reg. No.	48,324

CERTIFICATE OF TRANSMISSION/MAILING			
I hereby certify that this correspondence is being facsimile transmitted to the USPTO or deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on the date shown below:			
Signature			
Typed or printed name	Vidya Ramsook-Gosine	Date	26 September 2005

This collection of information is required by 37 CFR 1.6. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.11 and 1.14. This collection is estimated to 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

SEP 27 2005

Patent Application 10/800,328
Attorney Docket No. PC25322A

1

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE APPLICATION OF: : Bright, et al
APPLICATION NO.: : Examiner: Unknown
FILING DATE: : 10/800,328
: Group Art Unit: Unknown
TITLE: : March 12, 2004
: PYRIDYLOXYMETHYL
AND BENZISOXAZOLE
AZABICYCLIC
DERIVATIVES

Mail Stop Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

Supplemental Preliminary Amendment

A Preliminary Amendment was filed on or about October 7, 2004. This Supplemental Preliminary Amendment is being filed to replace said Preliminary Amendment. A listing of the claims is provided herein and replaces all claims previously filed. Furthermore, this amendment will correct typographical errors identified in the specification. It is believed that no office action has issued and Applicants request entry of this Supplemental Preliminary Amendment.

Please amend the above-identified application as follows:

Amendments to the Specification are reflected in the replacement paragraphs beginning on page 3 of this paper.

Please replace the following paragraphs:

Page 1, paragraphs [0008] to [0009] as they appear in US 2005/0026922A1, which correspond with page 2, lines 19-23 of the application as filed.

Patent Application 10/800,328
Attorney Docket No. PC25322A

2

Page 2, paragraphs [0019] to [0020] as they appear in US 2005/0026922A1, which correspond with Page 3, line 21 spanning to page 4, line 3.

Page 7, paragraphs [0083] to [0084] as they appear in US 2005/0026922A1, which correspond with page 14, lines 17-20.

Amendments to the Claims are reflected in the listing of claims which begins on page 6 of this paper. In the previously filed Preliminary Amendment, 34 was inadvertently used twice. The second claim 34 has been renumbered herein as claim 35. This numbering is used to explain the amendments addressed herein.

Claims 1-31 were previously canceled.

Please cancel claims 32-35.

Please add new claims 36-39.

Remarks begin on page 12 of this paper.